| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |



From the Department of Pathology and Oncology,
*
School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; the Department of Pathology,
Faculty of Medicine, University of Tokyo Hospital, Tokyo, Japan; and the Department of Pathology,
Cancer Hospital, Shanghai Medical University, Shanghai, Peoples Republic of China
The fibrosarcomatous transformation of dermatofibrosarcoma protuberans (DFSP) has been considered for some time to be associated with an adverse clinical outcome. However, the molecular and cellular mechanism underlying the tumor progression remains undetermined. As the chimeric gene, COL1A1-PDGFB, has been proposed to play an important role in the histogenesis of DFSP, we conducted a reverse transcription-polymerase chain reaction assay to ascertain whether the COL1A1-PDGFB fusion transcripts can be detected in both conventional DFSP and fibrosarcomatous components of DFSP with fibrosarcomatous areas (DFSP-FS), using a simple method of microdissection on sections of archival formalin-fixed, paraffin-embedded tumor specimens from six DFSP-FS cases. The COL1A1-PDGFB fusion transcripts could be detected in FS areas in five of the six cases, whereas conventional DFSP areas of all cases expressed the chimeric mRNA. A subsequent sequence analysis of the polymerase chain reaction products confirmed that the detected messages were derived from identical gene fusions in the two different components of each of the five cases. Our results verify that the COL1A1-PDGFB fusion transcripts are preserved in the FS areas of most DFSP-FSs. The expression of the fusion transcripts in both conventional DFSP and FS areas of DFSP-FS supports a common histogenesis of the two components.
This article has been cited by other articles:
![]() |
D. Kerob, F. Pedeutour, C. Leboeuf, O. Verola, E. de Kerviler, J. M. Servant, F. Sarandi, G. Bousquet, I. Madelaine-Chambrin, C. Pruvost, et al. Value of Cytogenetic Analysis in the Treatment of Dermatofibrosarcoma Protuberans J. Clin. Oncol., April 1, 2008; 26(10): 1757 - 1759. [Full Text] [PDF] |
||||
![]() |
G. Maire, S. Fraitag, L. Galmiche, F. Keslair, N. Ebran, M.-J. Terrier-Lacombe, Y. de Prost, and F. Pedeutour A Clinical, Histologic, and Molecular Study of 9 Cases of Congenital Dermatofibrosarcoma Protuberans Arch Dermatol, February 1, 2007; 143(2): 203 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Szollosi, B. Scholtz, K. Egervari, and Z. Nemes Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas J. Clin. Pathol., February 1, 2007; 60(2): 190 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
W Gu, A Ogose, H Kawashima, H Umezu, N Kudo, T Hotta, and N Endo Congenital dermatofibrosarcoma protuberans with fibrosarcomatous and myxoid change J. Clin. Pathol., September 1, 2005; 58(9): 984 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tsao Genetics of Nonmelanoma Skin Cancer Arch Dermatol, November 1, 2001; 137(11): 1486 - 1492. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |